Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It stopped about 45 minutes after market close plus I was watching it on IHUB so maybe it had something to do with that. Usually check it on my computer.
Anyone notice the ask looks similar to that of a moving target after hours?
Well the smartest of the smart money investors just paid 13.50 and they were lucky to get that share price. Regardless of there reasons for buying (grab a piece of the pie or to cover) the deal with Amgen has opened a few eyes. I don't know what will happen tomorrow but I think the algos are about to swing in our favor and the remaining shorts know it. Smart money knows another great PR is eminent.
I'd definitely do it before the 30 million gets finalized tomorrow because Monday we will look like a horse of another color.
James is there any way you can think of where the buyers wouldn't have to file their position? Say if this stock purchase was divided up among say 10 buyers or if it was used to cover a short position etc.
If the ceo hadn't shown us the true nature of his character in the first year of his tenure this wouldn't be as big of an issue but, well, he did reveal himself to all of us.
If you don't find the timing of the sell of these shares to be in poor taste, once again, I wouldn't be investing in the biotechnology sector. I'm merely saying what's on a lot of our minds.
And that is all I was getting at FBG. I love the company and the science but sometimes find myself scratching my head thinking, "did that just happen?"
That will be interesting.
I'm hopeful that's the case HD.
Not a conspiracy theorist at all, I have been invested in Advaxis for quite a while though (almost a decade). I personally have never praised Dan. I stay invested here In hopes the Science will overcome the obstacles in front of it. I have also developed a discerning eye for good science and BS in the eight years I have been invested here. I have also developed a pretty thick skin for people who try and ridicule others for not having their same exact flawed thoughts. If you think everyone in the market plays by the rules and are fine upstanding folks you should probably not be invested in biotechs.
Anyone who has been invested in this company longer then DO has been around has had the opportunity to get to know Dan before we had large institutional shareholders to keep his greed in line. When Dan thinks nobody is watching him he is capable of being a criminal. That is your basic personality my friend, what you are capable of doing when you think you won't get caught.
This is why when Dan pulls stunts like this the market get a reminder of events past and he loses any credibility he may have gained
Cash burn rate of 5 mill per month is what I meant to type.
We didn't need the money mastiffs, even James who is usually very reserved agrees with that point. The company had cash reserves to last 2 years with a cash burn of 5 mill per year. The money could have been raised at a potentially much higher share pruce.
Yeah, I'm looking forward to a big run from here HD!
Yeah, I think our ascent will be unimpeded now.
I will also bet you we get a game changing PR in the next couple of weeks though as well.
I'll bet 2.2 million shares is the exact amount of shares that we had left to cover. Of course they wanted the shares.
I don't disagree with what you are saying but we did just raise 65 million a week ago so we should have around 160 million in bank without the 30 million the sold today.
Only one possible positive thing that might come out of this and that is if the company has a huge PR to kick out and wanted the shorts and their HFT BS out of the way. So selling these shares gets them out of the way?
I like a lot of you post but why would It be the investment banks business as to what their customer is going to do with the shares. Party A wants shares, party B likes the price somewhat so the investment bank arranges the deal. That's the Beauty of a short, you don't have to report your position publicly.
Since when does the SEC enforce anything. It would be impossible to prove since shorts don't have to report their position.
He just helped our short friends cover
Well what has just happened is Dan took potential revenue out of your pocket and placed it in someone elses. You'll get about 13% less now for any potential offer for the company That money wasn't need currently, it was obviously a back door cap deal.
The amgen deal was worth 40 million in cash and 25 million for 3 million. Shares of stock for a total of 65 million. We had roughly 95 million in the bank so what gives? With both deals we have been diluted about13% in two weeks.
Probably Dan securing votes if challenged by a large investor. These discounts to market are ridiculous.
Probably being used to cover a short.
It is a weak move.
Why, when we have 165 million already in the bank? This mindset of constantly selling shares to whomever wants them is ridiculous.
I think maybe Advaxis signed the neo-epitope deal to get into play now rather then waiting and giving any competition time to catch up as time is a factor. This whole deal may come down to the company with the best tech (Advaxis) locking up as many deals as possible for their constructs and blocking out the competition. I think HPV with Astra is being signed as we speak. They are interested in cervical and head and neck so the PR yesterday might indicate they have all the data they need to complete a deal. I think they will keep anal for themselves as they are batting near 100% without combo help. JMO.
I believe I said our drugs couldn't be copied. Your looking for something to debate. If you think Aduro has a better product (not even close), then I suggest you invest there.
Aduro's drug rally isn't very similar and is lacking a lot of the more important characteristics that make Yvonne's bacteria efficacios. It won't be a problem.
Look up orphan designation. We have orphan designation on almost all of our constructs.
After all of this discussion about patents, they won't matter so long as we are first to market with our constructs. We get 5 years of exclusivity for all non orphan designated drugs and seven for constructs with orphan designation. Get these to the market and they can't be copied even if patents run out.
BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces that the United States Patent and Trademark Office (USPTO) has confirmed the patentability of its U.S. Patent 7,842,289 (‘289 patent) at the successful conclusion of an ex parte reexamination proceeding initiated by Advaxis Incorporated (OTCBB: ADXS). During the proceeding, the USPTO rejected Advaxis’ assertions of invalidity, and confirmed that the claims are patentable as originally issued and without amendment. The proceeding has now completed with the issuance of Ex Parte Reexamination Certificate US 7,842,289 C1 on November 1, 2011.
“We have built a broad portfolio of patents to protect our platform”
Tweet this
Aduro’s ’289 patent relates to Aduro’s proprietary Listeria monocytogenes (Listeria) platform that is used in Aduro's live-attenuated vaccine strains. Aduro’s technology enhances the expression of antigens by the bacterium, which in turn has been shown to increase potency of the induced immune response. “We have built a broad portfolio of patents to protect our platform,” said Thomas Dubensky, Chief Scientific Officer of Aduro BioTech, “and this reexamination provides further validation of the strength of our intellectual property position. We will continue to build the value of our IP portfolio as we advance our proprietary technology towards commercialization.”
Aduro’s intellectual property portfolio includes a number of issued patents, both in the United States and in various foreign countries, related to company’s proprietary Listeria platform. The intellectual property includes patents and patent applications directed to methods for attenuating the Listeria bacterium to improve its safety in vaccine
ADURO doesn't seem to think it will be in 2017.
I do know aduro used to refer to their bacteria as double deleted, metabolically inactive and now refer to it as live attenuated double deleted.
There you go, they have to make investors aware that there has been a conflict but patents won't be an issue.
The us court said double deleted metabolically inactive Was different enough from ADXS's bacteria that they weren't infringing on our patent's. What about this would prohibit them from selling their product In the US?
They won the battle in the us and that is why they still exist. European courts said that indeed it was patent infringement.